-
6. VISION IMPAIRMENT: AN UNUSUAL INITIAL PRESENTATION OF NASOPHARYNGEAL CARCINOMA
MALAYSIAN JOURNAL OF SCIENCE, HEALTH & TECHNOLOGY
2021 OTHER DATABASE MAIN AUTHOR / CONTACT PERSON IN USIM -
7. PYOGENIC GRANULOMA OF INFERIOR TURBINATE IN CHILDREN: COMMON SYMPTOMS WITH A RARE DIAGNOSIS
MALAYSIAN JOURNAL OF SCIENCE HEALTH AND TECHNOLOGY (MJOSHT)
2021 OTHER DATABASE CO-AUTHOR -
8. VIRAL LOAD, DETECTION RATE AND SENSITIVITY OF NASOPHARYNGEAL AND OROPHARYNGEAL SWAB SAMPLING FOR DIAGNOSIS OF COVID-19
ULUM ISLAMIYYAH JOURNAL
2021 ERA CO-AUTHOR -
9. EPISTAXIS SECONDARY TO RHINOLITH: A FORGOTTEN AND SCARCE ENTITY
MALAYSIAN JOURNAL OF SCIENCE, HEALTH & TECHNOLOGY (MJOSHT)
2021 OTHER DATABASE CO-AUTHOR -
10. NARRATIVE REVIEW OF TRACHEOSTOMY PROCEDURE DURING COVID-19 PANDEMIC
ULUM ISLAMIYYAH JOURNAL
2021 ERA CORRESPONDING AUTHOR
ACADEMIC QUALIFICATIONS
- Sarjana Kepakaran in Otorinolaringologi - Surgeri K (2019)
- Bachelor in Medicine (2009)
EXPERTISE
- Otorhinolaryngology-Head And Neck Surgery (Orl-Hns)
- Clinical Education, Mentoring And Mentorship
- Clinical Research
DR. NOR AZIRAH BINTI SALAHUDDINPENSYARAH PERUBATAN DU14 Faculty Fakulti Perubatan Dan Sains Kesihatan Biography A lecturer from Fakulti Perubatan Dan Sains Kesihatan. Holds a Sarjana Kepakaran in Otorinolaringologi - Surgeri K. Usim Expert: https://expert.usim.edu.my/norazirah Phone: 067985002 E-mail: norazirah@usim.edu.my |
RESEARCHER
ID
|
-
1. ANTIMICROBIAL ACTIVITY OF MALAYSIAN HONEY AGAINST COMMON PATHOGENS IN ACUTE OTITIS EXTERNA : AN IN VITRO STUDY
2022 GERAN PENYELIDIKAN USIM ON GOING MAIN RESEARCHER -
2. THE DEVELOPMENT AND FEASIBILITY STUDY OF 3D PRINTED MATERIAL USE IN NASOPHARYNGEAL SWAB FOR COVID 19 TESTING
2020 GERAN PENYELIDIKAN COVID-19 COMPLETED CO-RESEARCHER -
3. PSYCHOPHYSIOLOGICAL STATUS OF MALAYSIAN YOUTH INVOLVE IN ESPORTS
2019 GERAN PENYELIDIKAN USIM COMPLETED CO-RESEARCHER -
4. EXPLORING CURRENT TRENDS IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA AMONG MALAYSIAN?S POPULATION
2019 GERAN PENYELIDIKAN USIM COMPLETED CO-RESEARCHER
Completed: 3 (75%)
Ongoing: 1 (25%)